Organon & Co has a consensus price target of $23 based on the ratings of 7 analysts. The high is $33 issued by Raymond James on March 16, 2023. The low is $15 issued by Morgan Stanley on April 9, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, Barclays, and Morgan Stanley on April 9, 2025, February 14, 2025, and February 14, 2025, respectively. With an average price target of $18.33 between Morgan Stanley, Barclays, and Morgan Stanley, there's an implied 63.69% upside for Organon & Co from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
04/09/2025 | Buy Now | 33.93% | Morgan Stanley | Terence Flynn65% | $16 → $15 | Maintains | Equal-Weight | Get Alert |
02/14/2025 | Buy Now | 114.29% | Barclays | Balaji Prasad51% | $26 → $24 | Maintains | Overweight | Get Alert |
02/14/2025 | Buy Now | 42.86% | Morgan Stanley | Terence Flynn65% | $17 → $16 | Maintains | Equal-Weight | Get Alert |
09/06/2024 | Buy Now | 78.57% | JP Morgan | Chris Schott59% | $18 → $20 | Downgrade | Neutral → Underweight | Get Alert |
05/06/2024 | Buy Now | 78.57% | Goldman Sachs | Chris Shibutani55% | $18 → $20 | Maintains | Neutral | Get Alert |
05/03/2024 | Buy Now | 78.57% | Goldman Sachs | Chris Shibutani55% | $18 → $20 | Maintains | Neutral | Get Alert |
04/29/2024 | Buy Now | 114.29% | Piper Sandler | David Amsellem69% | $22 → $24 | Maintains | Overweight | Get Alert |
02/20/2024 | Buy Now | 60.71% | Goldman Sachs | Chris Shibutani55% | $16 → $18 | Maintains | Neutral | Get Alert |
11/22/2023 | Buy Now | 96.43% | Piper Sandler | David Amsellem69% | $32 → $22 | Maintains | Overweight | Get Alert |
11/03/2023 | Buy Now | 42.86% | Goldman Sachs | Chris Shibutani55% | $33 → $16 | Downgrade | Buy → Neutral | Get Alert |
10/25/2023 | Buy Now | 185.71% | Piper Sandler | David Amsellem69% | $33 → $32 | Maintains | Overweight | Get Alert |
10/11/2023 | Buy Now | 96.43% | Morgan Stanley | Terence Flynn65% | $27 → $22 | Maintains | Equal-Weight | Get Alert |
09/21/2023 | Buy Now | 150% | Barclays | Balaji Prasad51% | → $28 | Initiates | → Overweight | Get Alert |
08/09/2023 | Buy Now | 141.07% | Morgan Stanley | Terence Flynn65% | $25 → $27 | Maintains | Equal-Weight | Get Alert |
05/08/2023 | Buy Now | 123.21% | Morgan Stanley | Terence Flynn65% | $26 → $25 | Maintains | Equal-Weight | Get Alert |
03/16/2023 | Buy Now | 194.64% | Raymond James | Elliot Wilbur45% | → $33 | Initiates | → Outperform | Get Alert |
11/04/2022 | Buy Now | 114.29% | Morgan Stanley | Terence Flynn65% | $27 → $24 | Maintains | Equal-Weight | Get Alert |
10/14/2022 | Buy Now | 123.21% | B of A Securities | Jason Gerberry61% | $37 → $25 | Downgrade | Neutral → Underperform | Get Alert |
10/12/2022 | Buy Now | 141.07% | Morgan Stanley | Terence Flynn65% | $35 → $27 | Maintains | Equal-Weight | Get Alert |
09/06/2022 | Buy Now | 203.57% | Piper Sandler | David Amsellem69% | $37 → $34 | Upgrade | Neutral → Overweight | Get Alert |
08/05/2022 | Buy Now | 230.36% | B of A Securities | Jason Gerberry61% | $40 → $37 | Downgrade | Buy → Neutral | Get Alert |
07/08/2022 | Buy Now | 203.57% | Morgan Stanley | Terence Flynn65% | $35 → $34 | Maintains | Equal-Weight | Get Alert |
04/27/2022 | Buy Now | 257.14% | Goldman Sachs | Chris Shibutani55% | → $40 | Initiates | → Buy | Get Alert |
The latest price target for Organon (NYSE:OGN) was reported by Morgan Stanley on April 9, 2025. The analyst firm set a price target for $15.00 expecting OGN to rise to within 12 months (a possible 33.93% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Organon (NYSE:OGN) was provided by Morgan Stanley, and Organon maintained their equal-weight rating.
The last upgrade for Organon & Co happened on September 6, 2022 when Piper Sandler raised their price target to $34. Piper Sandler previously had a neutral for Organon & Co.
The last downgrade for Organon & Co happened on September 6, 2024 when JP Morgan changed their price target from $18 to $20 for Organon & Co.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Organon, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Organon was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.
While ratings are subjective and will change, the latest Organon (OGN) rating was a maintained with a price target of $16.00 to $15.00. The current price Organon (OGN) is trading at is $11.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.